The Pharmaceutical Management Branch (PMB) is charged with providing pharmaceutical support for clinical trials sponsored by the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP). This support includes:
- authorization and distribution of all CTEP-sponsored Investigational New Drug (IND) agents to eligible investigators
- provision of agent forecasting, agent acquisition, and inventory management of all IND agents distributed by CTEP for clinical trials
- provision of pharmaceutical information about CTEP IND agents
- coordination, authorization, and processing of all requests for Special Exception and Treatment Referral Center (TRC) IND agent use
- registration of all investigators participating in CTEP clinical trials and the maintenance of all registration records
- provision and management of high priority double blind, randomized clinical trials
- development and maintenance of a Treatment Referral Center for handling special CTEP clinical agent initiatives and referrals to high priority clinical trials
- distribution of agents to investigators for non-human (preclinical) use
|
